Form 4: Spyre CFO Exercises Options, Sells Shares Under 10b5-1 Plan

Spyre Therapeutics' CFO, Scott L. Burrows, exercised stock options and subsequently sold a portion of the acquired common stock on March 3, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), engaged in transactions involving the company's common stock on March 3, 2026.
• Burrows exercised options to acquire 2,500 shares of common stock at an exercise price of $14.50 per share.
• Following the option exercise, Burrows sold a total of 2,500 shares of common stock in two separate transactions.
• The first sale involved 2,300 shares at a weighted average price of $40.56 per share, with prices ranging from $40.17 to $41.11.
• The second sale involved 200 shares at a weighted average price of $41.66 per share, with prices ranging from $41.55 to $41.76.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
• After these transactions, Burrows directly beneficially owns 97,994 shares of common stock, which includes 67,476 restricted stock units (RSUs).
• Burrows also holds stock options to purchase 402,357 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a pre-arranged 10b5-1 plan for a relatively small portion of total holdings suggests routine personal financial management rather than a bearish outlook on the company.

Positives

• The exercise of stock options at $14.50 and subsequent sale at average prices of $40.56 and $41.66 indicates a profitable transaction for the insider, reflecting a significant increase in the company's stock value since the options were granted.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations, suggesting a planned and transparent approach to managing personal holdings.

Negatives

• The sale of 2,500 shares by a Chief Financial Officer, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence in the company's near-term stock price appreciation, although it is often for personal liquidity.

Future Outlook

The filing indicates future vesting events for 67,476 restricted stock units, with equal installments scheduled for September 1, 2026, and September 1, 2027, contingent on continued employment. Additionally, the remaining three quarters of the 404,857 stock options will continue to vest in monthly installments over the next three years, subject to the same employment condition.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors like Spyre Therapeutics. While the sale of shares by a CFO might typically raise questions, the pre-arranged nature of the 10b5-1 plan often mitigates concerns about opportunistic selling, suggesting personal financial planning rather than a reaction to undisclosed material information. Such transactions are generally viewed as routine for executives managing their equity compensation.

Comparison to Industry Standards

• Insider selling by executives is a common occurrence across industries, particularly when equity compensation forms a significant portion of their remuneration. For example, executives at companies like Pfizer or Moderna frequently utilize 10b5-1 plans to systematically diversify their holdings or manage liquidity needs.
• The exercise of options at a significantly lower price than the sale price, as seen here, is a standard outcome of long-term incentive plans designed to reward executives for stock appreciation.
• The volume of shares sold (2,500) relative to the total options held (over 400,000) and RSUs (over 67,000) suggests a relatively small, routine liquidation rather than a significant divestment of holdings, aligning with typical executive financial planning practices.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the CFO's sale as a neutral event due to the 10b5-1 plan, or potentially as a minor negative signal if they overlook the plan's context. The profitable exercise and sale could also be seen as a positive for executive compensation alignment.

Next Steps

• Remaining three quarters of stock options will continue to vest in monthly installments over the next three years, subject to continued employment.
• First equal installment of 67,476 restricted stock units (RSUs) vests on September 1, 2026.
• Second equal installment of 67,476 restricted stock units (RSUs) vests on September 1, 2027.

Key Dates

Recommendation

The transactions reported are routine insider activity under a pre-arranged 10b5-1 plan, indicating personal financial management rather than a change in the company's fundamental outlook. While the CFO sold shares, the volume is not exceptionally large relative to total holdings, and the plan mitigates concerns of opportunistic selling. Therefore, the filing alone does not provide sufficient new information to warrant a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Stock Options, Share Sale, CFO, Scott L. Burrows, 10b5-1 Plan, Restricted Stock Units